Evidence map›Paper›PMID 34123384›Full record

ArticleRespirology case reports2021

Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase-positive non-small cell lung cancer with triple problems: carcinomatous meningitis, poor performance status, and dysphagia-a case report.

Kota Sasaki, Yusuke Yokota, Toshihito Isojima, Mayumi Fujii, Kengo Hasui, Yu Chen, Kensuke Saito, Takenori Takahata, Seiko Kindaichi, Atsushi Sato

Open access · goldAbstract readCase Reports
In one paragraph

Article in Respirology case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Kota SasakiDepartment of Medical Oncology Hirosaki University Graduate School of Medicine Aomori Japan.ORCID https://orcid.org/0000-0002-0746-4487
Yusuke YokotaDepartment of Internal medicine Aomori Kyoritsu Hospital Aomori Japan.
Toshihito IsojimaDepartment of Internal medicine Aomori Kyoritsu Hospital Aomori Japan.
Mayumi FujiiDepartment of Pharmacy Aomori Kyoritsu Hospital Aomori Japan.
Kengo HasuiDepartment of Medical Oncology Hirosaki University Graduate School of Medicine Aomori Japan.
Yu ChenDepartment of Medical Oncology Hirosaki University Graduate School of Medicine Aomori Japan.
Kensuke SaitoDepartment of Medical Oncology Hirosaki University Graduate School of Medicine Aomori Japan.
Takenori TakahataDepartment of Medical Oncology Hirosaki University Graduate School of Medicine Aomori Japan.
Seiko KindaichiDepartment of Pharmacy Aomori Kyoritsu Hospital Aomori Japan.
Atsushi SatoDepartment of Medical Oncology Hirosaki University Graduate School of Medicine Aomori Japan.
Hirosaki University · JPAomori Rosai Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alectinib treatment is effective in patients with anaplastic lymphoma kinase

Indexed as

ALK inhibitorbrain metastasiscomatosenasogastric tubesimple suspension method

Identifiers

PMID34123384
PMCPMC8173452
OpenAlexW3170658390

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.